Pharmaceutical Executive-10-01-2016

A practical roadmap for pharma brand teams in avoiding the pitfalls in statistical thinking when appraising and presenting data.

Today’s C-suite executives in the life sciences must be experts in many disciplines. Pharm Exec examines the evolving role of the chief financial officer as not just a numbers and bottom-line risk manager but an integral contributor to overall corporate strategy and close partner to the CEO.

When lobbying tips the scales: a path to drug approval.

The latest price rules revision is both radical and rare by the government’s usual exhaustive standards. What do the new rules mean for pharma players in the world’s third-largest market?

Pharm Exec convenes an expert Roundtable to discuss one of the hottest topics in big data today-how to make that data relevant to payers, regulators and the patient through reliance on real-world evidence in driving better health outcomes.

The potential collapse of the CETA agreement jeopardizes EU’s overall trade footing.

Survey on the rising use of Inter Partes Reviews to challenge patents reveals key considerations for originator companies.

PDUFA VI to enhance FDA staffing, revise fees and expand evidence for drug development.

Though comparatively smaller when positioned against some of the country’s neighbors, the pharmaceutical market in the Czech Republic finds itself on a solid growth trajectory, with innovator drug developers grabbing a larger piece of the value pie in the traditionally generics- dominated setting.

Click the title above to open the Pharmaceutical Executive October 2016 issue in an interactive PDF format.